Contribution of ADA1A polymorphism to persistent pain states

ADA1A 多态性对持续性疼痛状态的影响

基本信息

  • 批准号:
    7485979
  • 负责人:
  • 金额:
    $ 4.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Millions of Americans suffer from unrelieved persistent pain, which has a devastating effect on their quality of life and severely burdens our health care system. There is growing evidence that intractable pain is frequently comorbid with anxiety, depression, and other psychological traits, often manifesting as hypersensitivity disorders in which the underlying physical substrate of the pain is unknown. The role of cognitive and affective risk factors in the development of these idiopathic pain conditions has not been adequately explored. A compelling explanation for the development of idiopathic disorders, such as fibromyalgia, irritable bowel syndrome, and temporomandibular joint disease (TMD), is disregulation of the adrenergic neurotransmitter system. Polymorphic variants of several genes encoding adrenergic receptors have been shown to elevate risk for developing TMD; these genes have also been associated with negative mood and cognitive effects. This proposal will investigate the relationship between alpha-adrenergic receptor (ADRA) gene polymorphisms and risk factors for chronic pain using genetic techniques and murine models of behavior. Our preliminary studies with a small prospective cohort showed a strong link between genetic variants of ADRA1A and risk of TMD development. Here we would like to employ a novel case control study population to verify and extend these preliminary findings. To confirm the contribution of alpha-adrenergic receptors to pain sensitivity and affective states in vivo, we will use mouse inflammatory pain and behavioral models. To investigate potential molecular mechanisms underlying the observed associations, individual variations in ADRA1A expression patterns will be studied in white blood cell samples collected from each subject enrolled in the study. These experiments will provide a better understanding of how adrenergic neuromodulation contributes to pathological nociceptive and affective states, ultimately leading to the development of a persistent pain condition. Identifying genetic and environmental risk factors for TMD will allow for the development of precise diagnostic tools, and provide novel targets for analgesic therapies. Determining the genetic and environmental risk factors for the development of persistent pain disorders such as TMD is crucial for diagnosing and treating these debilitating diseases. This proposal will explore the causes of TMD in a population of chronic pain patients, and investigate the molecular mechanisms by which adrenergic receptors contribute to pain sensitivity and negative mood traits.
数百万美国人患有无法缓解的持续性疼痛,这对他们的生活质量产生了毁灭性的影响,并严重负担了我们的医疗保健系统。越来越多的证据表明,顽固性疼痛经常与焦虑、抑郁和其他心理特征共病,通常表现为超敏反应性疾病,其中疼痛的潜在物理基础未知。认知和情感风险因素在这些特发性疼痛疾病发展中的作用尚未得到充分研究。对于特发性疾病,如纤维肌痛、肠易激综合征和颞下颌关节病(TMD)的发展,一个令人信服的解释是肾上腺素能神经递质系统的失调。编码肾上腺素能受体的几个基因的多态性变体已被证明会增加患TMD的风险;这些基因也与负面情绪和认知影响有关。本研究将利用遗传学技术和小鼠行为模型研究α-肾上腺素能受体(ADRA)基因多态性与慢性疼痛危险因素之间的关系。我们对一个小型前瞻性队列的初步研究显示,ADRA 1A的遗传变异与TMD发展风险之间存在密切联系。在这里,我们想采用一种新的病例对照研究人群来验证和扩展这些初步研究结果。为了证实α-肾上腺素能受体对体内疼痛敏感性和情感状态的贡献,我们将使用小鼠炎症疼痛和行为模型。为了研究观察到的相关性的潜在分子机制,将在从入组研究的每例受试者采集的白色血细胞样本中研究ADRA 1A表达模式的个体差异。这些实验将更好地了解肾上腺素能神经调节如何促进病理性伤害感受和情感状态,最终导致持续性疼痛状况的发展。确定TMD的遗传和环境风险因素将有助于开发精确的诊断工具,并为镇痛治疗提供新的靶点。确定导致持续性疼痛疾病(例如TMD)发展的遗传和环境风险因素对于诊断和治疗这些使人衰弱的疾病至关重要。本研究将探讨慢性疼痛患者中TMD的病因,并研究肾上腺素能受体对疼痛敏感性和消极情绪特征的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shad Benjamin Smith其他文献

Shad Benjamin Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shad Benjamin Smith', 18)}}的其他基金

Single-cell omics approaches to investigate TMD
研究 TMD 的单细胞组学方法
  • 批准号:
    10524285
  • 财政年份:
    2022
  • 资助金额:
    $ 4.83万
  • 项目类别:
Contribution of ADA1A polymorphism to persistent pain states
ADA1A 多态性对持续性疼痛状态的影响
  • 批准号:
    7864158
  • 财政年份:
    2008
  • 资助金额:
    $ 4.83万
  • 项目类别:
Contribution of ADA1A polymorphism to persistent pain states
ADA1A 多态性对持续性疼痛状态的影响
  • 批准号:
    7652474
  • 财政年份:
    2008
  • 资助金额:
    $ 4.83万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 4.83万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 4.83万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 4.83万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 4.83万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 4.83万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 4.83万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 4.83万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 4.83万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 4.83万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 4.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了